LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,563
تعداد دریافت فایل اصل مقاله11,291,383
Rahimzadeh, Golnar, Resch, Gregory, Rezai, Mohammad Sadegh, Nemati Hevelaee, Ebrahim. (1399). Characterization and Lytic Activity of Isolated Escherichia Coli Bacteriophages against Escherichia Coli in Vitro. سامانه مدیریت نشریات علمی, 45(4), 298-303. doi: 10.30476/ijms.2019.45420
Golnar Rahimzadeh; Gregory Resch; Mohammad Sadegh Rezai; Ebrahim Nemati Hevelaee. "Characterization and Lytic Activity of Isolated Escherichia Coli Bacteriophages against Escherichia Coli in Vitro". سامانه مدیریت نشریات علمی, 45, 4, 1399, 298-303. doi: 10.30476/ijms.2019.45420
Rahimzadeh, Golnar, Resch, Gregory, Rezai, Mohammad Sadegh, Nemati Hevelaee, Ebrahim. (1399). 'Characterization and Lytic Activity of Isolated Escherichia Coli Bacteriophages against Escherichia Coli in Vitro', سامانه مدیریت نشریات علمی, 45(4), pp. 298-303. doi: 10.30476/ijms.2019.45420
Rahimzadeh, Golnar, Resch, Gregory, Rezai, Mohammad Sadegh, Nemati Hevelaee, Ebrahim. Characterization and Lytic Activity of Isolated Escherichia Coli Bacteriophages against Escherichia Coli in Vitro. سامانه مدیریت نشریات علمی, 1399; 45(4): 298-303. doi: 10.30476/ijms.2019.45420

Characterization and Lytic Activity of Isolated Escherichia Coli Bacteriophages against Escherichia Coli in Vitro

Iranian Journal of Medical Sciences
مقاله 8، دوره 45، شماره 4، مهر 2020، صفحه 298-303    اصل مقاله (1.19 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2019.45420
نویسندگان
Golnar Rahimzadeh1؛ Gregory Resch2؛ Mohammad Sadegh Rezai* 1؛ Ebrahim Nemati Hevelaee3
1Pediatric Infectious Diseases Research Center, Mazandaran University of Medical Sciences, Sari, Iran
2Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland
3Laboratory of microbiology, Bouali Sina Hospital, Mazandaran University of Medical Sciences, Sari, Iran
چکیده
Background: Escherichia coli (E. coli) is the most common cause of urinary tract infection (UTI) and typically treated with antibiotics. Unrestricted use of antibiotics may lead to the emergence of antibiotic-resistant bacteria. The present study aimed to isolate and characterize phages against E. coli from infected urine samples and to determine the lytic activity of phages against E. coli in vitro.
Methods: The present experimental study was conducted in the Laboratory of Bouali Sina Hospital (Sari, Iran) in May 2018. E. coli was identified from nine urine samples of patients with UTI using conventional microbiological methods. Bacteriophages were isolated from the infected urine specimens, and their lytic activity was determined using the spot test. The titer of the bacteriophages was measured using the double-layer agar technique. The morphology of the bacteriophages was revealed using transmission electron microscopy, and the latent time period and burst size were determined. Data were analyzed using the SPSS software package.
Results: E. coli was isolated from nine infected urine samples. The lytic activity of bacteriophages against E. coli was determined using the spot test by observing the formation of inhibition zones. Transmission electron microscopy showed E. coli phages belonging to the Myoviridae family. The latent time period was 20 minutes with a burst size of 1,200 plaque-forming unit (PFU) per infected cell. The results of the double-layer agar assay showed that the titer of bacteriophages was 20×108 PFU/mL.
Conclusion: The E. coli bacteriophage was isolated from infected urine samples and characterized, and their lytic activity against E. coli was determined in vitro.
کلیدواژه‌ها
Escherichia coli؛ Bacteriophages؛ Urinary tract infections
سایر فایل های مرتبط با مقاله
مراجع
  1. Sefton AM. The impact of resistance on the management of urinary tract infections. Int J Antimicrob Agents. 2000;16:489-91. PubMed PMID: 11118864. doi: 10.1016/S0924-8579(00)00282-X.
  2. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39:1211-33. doi: 10.1128/aac.39.6.1211. PubMed PMID: 7574506; PubMed Central PMCID: PMCPMC162717.
  3. Enne VI, Livermore DM, Stephens P, Hall LM. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet. 2001;357:1325-8. doi: 10.1016/S0140-6736(00)04519-0. PubMed PMID: 11343738.
  4. Romero L, Lopez L, Rodriguez-Bano J, Ramon Hernandez J, Martinez-Martinez L, Pascual A. Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases. Clin Microbiol Infect. 2005;11:625-31. doi: 10.1111/j.1469-0691.2005.01194.x. PubMed PMID: 16008614.
  5. Cabal A, Garcia-Castillo M, Canton R, Gortazar C, Dominguez L, Alvarez J. Prevalence of Escherichia coli Virulence Genes in Patients with Diarrhea and a Subpopulation of Healthy Volunteers in Madrid, Spain. Front Microbiol. 2016;7:641. doi: 10.3389/fmicb.2016.00641. PubMed PMID: 27199966; PubMed Central PMCID: PMCPMC4859089.
  6. Li Q, Lee JY, Castillo R, Hixon MS, Pujol C, Doppalapudi VR, et al. NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against beta-lactamase-producing strains. Antimicrob Agents Chemother. 2002;46:1262-8. doi: 10.1128/aac.46.5.1262-1268.2002. PubMed PMID: 11959554; PubMed Central PMCID: PMCPMC127132.
  7. Ma J, Liu JH, Lv L, Zong Z, Sun Y, Zheng H, et al. Characterization of extended-spectrum beta-lactamase genes found among Escherichia coli isolates from duck and environmental samples obtained on a duck farm. Appl Environ Microbiol. 2012;78:3668-73. doi: 10.1128/AEM.07507-11. PubMed PMID: 22407683; PubMed Central PMCID: PMCPMC3346353.
  8. Mirsalehian.A, Nakhjavani.F, Peymani.A, JabalAmeli.F, Mirafshar.S M, Hamidian.M. Frequency of extended spectrum β-Lactamase producing Enterobacteriaceae in intensive care units. Tehran University Medical Journal. 2008;65:33-8.
  9. Keen EC. A century of phage research: bacteriophages and the shaping of modern biology. Bioessays. 2015;37:6-9. doi: 10.1002/bies.201400152. PubMed PMID: 25521633; PubMed Central PMCID: PMCPMC4418462.
  10. Rahimzadeh G, Saeedi M, Farshidi F, Rezai MS. Phage Therapy in Treatment of Gram-negative Bacterial Infections: A Systematic Review. Journal of Mazandaran University of Medical Sciences. 2018;28:203-12.
  11. Sulakvelidze A, Alavidze Z, Morris JG, Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45:649-59. doi: 10.1128/AAC.45.3.649-659.2001. PubMed PMID: 11181338; PubMed Central PMCID: PMCPMC90351.
  12. Brussow H. Phage therapy: the Escherichia coli experience. Microbiology. 2005;151:2133-40. doi: 10.1099/mic.0.27849-0. PubMed PMID: 16000704.
  13. Khan Mirzaei M, Nilsson AS. Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS One. 2015;10:e0118557. doi: 10.1371/journal.pone.0118557. PubMed PMID: 25761060; PubMed Central PMCID: PMCPMC4356574.
  14. Dalmasso M, Strain R, Neve H, Franz CM, Cousin FJ, Ross RP, et al. Three New Escherichia coli Phages from the Human Gut Show Promising Potential for Phage Therapy. PLoS One. 2016;11:e0156773. doi: 10.1371/journal.pone.0156773. PubMed PMID: 27280590; PubMed Central PMCID: PMCPMC4900583.
  15. Jamalludeen N, She YM, Lingohr EJ, Griffiths M. Isolation and characterization of virulent bacteriophages against Escherichia coli serogroups O1, O2, and O78. Poult Sci. 2009;88:1694-702. doi: 10.3382/ps.2009-00033. PubMed PMID: 19590085.
  16. Snyder AB, Perry JJ, Yousef AE. Developing and optimizing bacteriophage treatment to control enterohemorrhagic Escherichia coli on fresh produce. Int J Food Microbiol. 2016;236:90-7. doi: 10.1016/j.ijfoodmicro.2016.07.023. PubMed PMID: 27454784.
  17. Perepanova TS, Darbeeva OS, Kotliarova GA, Kondrat’eva EM, Maiskaia LM, Malysheva VF, et al. [The efficacy of bacteriophage preparations in treating inflammatory urologic diseases]. Urol Nefrol (Mosk). 1995:14-7. PubMed PMID: 8571474.
  18. Chibeu A, Lingohr EJ, Masson L, Manges A, Harel J, Ackermann HW, et al. Bacteriophages with the ability to degrade uropathogenic Escherichia coli biofilms. Viruses. 2012;4:471-87. doi: 10.3390/v4040471. PubMed PMID: 22590682; PubMed Central PMCID: PMCPMC3347319.
  19. Sybesma W, Zbinden R, Chanishvili N, Kutateladze M, Chkhotua A, Ujmajuridze A, et al. Bacteriophages as Potential Treatment for Urinary Tract Infections. Front Microbiol. 2016;7:465. doi: 10.3389/fmicb.2016.00465. PubMed PMID: 27148173; PubMed Central PMCID: PMCPMC4826877.
  20. Niranjan V, Malini A. Antimicrobial resistance pattern in Escherichia coli causing urinary tract infection among inpatients. Indian J Med Res. 2014;139:945-8. PubMed PMID: 25109731; PubMed Central PMCID: PMCPMC4165009.
  21. Tuem KB, Gebre AK, Atey TM, Bitew H, Yimer EM, Berhe DF. Drug Resistance Patterns of Escherichia coli in Ethiopia: A Meta-Analysis. Biomed Res Int. 2018;2018:4536905. doi: 10.1155/2018/4536905. PubMed PMID: 29854757; PubMed Central PMCID: PMCPMC5960519.
  22. Forbes BA, Sahm DF, Weissfeld AS. Bailey & Scott’s Diagnostic Microbiology. 10th ed. Louis: Mosby: 1999.
  23. Rahimzadeh G, Gill P, Rezai MS. Characterization of methicillin-resistant Staphylococcus aureus (MRSA) phages from sewage at a tertiary pediatric hospital. Arch Pediatr Infect Dis. 2017;5:e39615. doi: 10.5812/pedinfect.39615.
  24. Rahimzadeh G, Gill P, Rezai MS. Characterization and lytic activity of methicillin-resistant Staphylococcus aureus (MRSA) phages isolated from NICU. Australas Med J. 2016;9:169-75. doi: 10.21767/AMJ.2016.2642.
  25. Nishikawa H, Yasuda M, Uchiyama J, Rashel M, Maeda Y, Takemura I, et al. T-even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections. Arch Virol. 2008;153:507-15. doi: 10.1007/s00705-007-0031-4. PubMed PMID: 18188500.
  26. Ghasemian A, Moradpour Z, Bavand M. A broad-host range coliphage against a clinically isolated E. coli O157: isolation and characterization. J Appl Pharm Sci. 2017;7:123-8. doi: 10.7324/JAPS.2017.70320.
  27. Majdani R. Isolation of lytic bacteriophages against pathogenic Escherichia coli strains in poultry in the northwest of Iran. Arch Razi Inst. 2016;71:235-44.
  28. Galtier M, De Sordi L, Maura D, Arachchi H, Volant S, Dillies MA, et al. Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low impact on microbiota composition. Environ Microbiol. 2016;18:2237-45. doi: 10.1111/1462-2920.13284. PubMed PMID: 26971586.
  29. Jamal M, Hussain T, Rajanna Das C, Andleeb S. Isolation and Characterization of a Myoviridae MJ1 Bacteriophage Against Multi-Drug Resistant Escherichia coli 3. Jundishapur J Microbiol. 2015;8:e25917. doi: 10.5812/jjm.25917. PubMed PMID: 26865936; PubMed Central PMCID: PMCPMC4744325.
  30. Pouillot F, Chomton M, Blois H, Courroux C, Noelig J, Bidet P, et al. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother. 2012;56:3568-75. doi: 10.1128/AAC.06330-11. PubMed PMID: 22491690; PubMed Central PMCID: PMCPMC3393425.
  31. Dufour N, Clermont O, La Combe B, Messika J, Dion S, Khanna V, et al. Bacteriophage LM33_P1, a fast-acting weapon against the pandemic ST131-O25b:H4 Escherichia coli clonal complex. J Antimicrob Chemother. 2016;71:3072-80. doi: 10.1093/jac/dkw253. PubMed PMID: 27387322.
آمار
تعداد مشاهده مقاله: 6,263
تعداد دریافت فایل اصل مقاله: 3,767


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب